|
Título:
|
Phase III Study of PSC-833 (Valspodar) in Combination with Vincristine, Doxorubicin, and Dexamethasone (Valspodar/VAD) versus VAD Alone in Patients with Recurring or Refractory Multiple Myeloma (E1A95)
|
|
Autor/a:
|
Friedenberg, William R.; Rué i Monné, Montserrat; Blood, Emily; Dalton, William S.; Shustik, Chaim; Larson, Richard A.; Sonneveld, Pieter; Greipp, Philip R.
|
|
Notas:
|
BACKGROUND. Preliminary studies have shown valspodar (PSC-833: Novartis Pharmaceuticals,
East Hanover, NJ) to be a potent inhibitor of multidrug resistance
(MDR), one cause of resistance to chemotherapy. An international randomized
control study (Phase III) evaluated the use of vincristine, doxorubicin, and dexamethasone
(VAD) with (n 46) and without (n 48) valspodar in the treatment of
patients with recurring or refractory multiple myeloma.
METHODS. Patients with documented recurrence or refractory myeloma were stratified
based on prior treatment exposure and creatinine and randomized. Because
of interaction of valspodar with vincristine and doxorubicin, the doses of these
drugs were reduced compared with the VAD-alone arm, and the doxorubicin was
further reduced in the last 15 patients when given with valspodar based on
pharmacokinetic and toxicity studies.
RESULTS. There were no complete or near-complete responses. There were 29%
partial responses (PRs) in the VAD-alone arm and 44% with valspodar (P 0.2).
Median progression-free survival was 7 months with VAD alone and 4.9 months
with valspodar (P 0.50). Subjective response was 19% with VAD alone and 17%
with valspodar (P 1.0). Median survival with VAD alone was 18.5 months and
15.3 with the addition of valspodar (P 0.055). Toxicity of Grade 3 or greater
was higher (P 0.0001) in the valspodar arm (89%) compared with the VAD-alone
arm (58%). The reduction of doxorubicin dose reduced toxicity but not significantly
(P 0.11).
CONCLUSION. The addition of the MDR-modulating agent valspodar to VAD did not
improve treatment outcome. Toxicity was increased in the valspodar-treated group
compared with VAD alone. |
|
Materia(s):
|
-Refractory multiple myeloma
-VAD
-Valspodar
-PSC-833 |
|
Derechos:
|
(c) American Cancer Society, 2006
info:eu-repo/semantics/restrictedAccess |
|
Tipo de documento:
|
article
publishedVersion |
|
Editor:
|
Wiley
|
|
Compartir:
|
|
